Potentially inappropriate medicines for older adults with intellectual disability: Clinical implications from a medication audit.
ageing individuals with intellectual disability
audit
medication review
polypharmacy
Journal
Australasian journal on ageing
ISSN: 1741-6612
Titre abrégé: Australas J Ageing
Pays: Australia
ID NLM: 9808874
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
12
11
2020
received:
28
04
2020
accepted:
19
11
2020
pubmed:
2
2
2021
medline:
21
9
2021
entrez:
1
2
2021
Statut:
ppublish
Résumé
To investigate medications that have the potential to be inappropriately prescribed for people with intellectual disability (ID) and to explore possible issues surrounding the potential harm that can result from the use of groups of medicines for people with ID who are ageing and living longer. An audit of medical case records of 350 patients under the care of an organisation in New Zealand was undertaken to examine existing medication profiles. Of the 350 patients, 95% were prescribed at least five or more medicines, with 7% of patients have 10 or more medicines. Increasing prescriptions are evident for those 56 years old and above. Medicines that may have been appropriate for people with intellectual disability when they were younger may have the potential to cause harm when they age. It is therefore important that monitoring and evaluation of medications for ageing individuals with intellectual disability are regularly undertaken.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e207-e214Informations de copyright
© 2021 AJA Inc.
Références
Ministry of Health New Zealand. Health Indicators for New Zealanders with Intellectual Disability 2011, Wellington NZ. https://www.health.govt.nz/publication/health-indicators-new-zealanders-intellectual-disability.Accessed October 13 2020.
Johansson M, Björne P, Runesson I, Ahlström G. Healthy ageing in people with intellectual disabilities from managers' perspective: a qualitative study. Healthcare (Basel). 2017;5(3):45. https://doi.org/10.3390/healthcare5030045
Haveman M, Heller T, Lee L, Maaskant M, Shooshtari S, Strydom A. Major health risks in aging persons with intellectual disabilities: an overview of recent studies. Journal of Policy and Practice in Intellectual Disabilities. 2010;7(1):59-69. https://doi.org/10.1111/j.1741-1130.2010.00248.x
Mark TL, Joish VN, Hay JW, Sheehan DV, Johnston SS, Zbun Cao MA. Antidepressant use in geriatric populations: The burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiatry. 2011;19(3):211-221. https://doi.org/10.1097/JGP.0b013e3181f1803d
Cadogan CA, Ryan C, Hughes CM. Appropriate polypharmacy and medicine safety: When many is not too many. Drug Saf. 2016;39(2):109-116. https://doi.org/10.1007/s40264-015-0378-5
Kaufman G. Polypharmacy in older adults. Nurs Stand. 2011;25(38):49-55.
Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008. BMC Clin Pharmacol. 2010;10:16. https://doi.org/10.1186/1472-6904-10-16
Huisman-Baron M, van der Veen L, Jansen P, van Roon EN, Brouwers JRBJ, van Marum RJ. Criteria for drug selection in frail elderly persons. Drugs Aging. 2011;28:391-402. https://doi.org/10.2165/11587200-000000000-00000
Franchi C, Tettamanti M, Pasina L, et al. Changes in drug prescribing to Italian community-dwelling elderly people: the EPIFARM-Elderly Project 2000-2010. Eur J Clin Pharmacol. 2014;70(4):437-443. https://doi.org/10.1007/s00228-013-1621-6
Gareri P, De Fazio P, De Fazio S, Marigliano N, Ferreri Ibbadu G, De Sarro G. Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging. 2006;23(12):937-956. https://doi.org/10.2165/00002512-200623120-00002
Dolder C, Nelson M, Stump A. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. Drugs Aging. 2010;27(8): 625-640. https://doi.org/10.2165/11537140-000000000-00000
Rikala M, Korhonen M, Sulkava R, Hartikainen S. Psychotropic drug use in community-dwelling elderly people-characteristics of persistent and incident users. Eur J Clin Pharmacol. 2011;67(7):731-739. https://doi.org/10.1007/s00228-011-0996-5
Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6-14. https://doi.org/10.1046/j.1365-2125.2003.02007.x
Giron MS, Forsell Y, Bernsten C, Thorslund M, Winblad B, Fastbom J. Psychotropic drug use in elderly people with and without dementia. Int J Geriatr Psychiatry. 2001;16:900-906. https://doi.org/10.1002/gps.438
Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67-76. https://doi.org/10.1080/03602530902722679
National Health Services. Medicines optimisation: clinical medication review A practice guide. In: Team NCMM, ed. England: National Health Services; 2014. https://www.england.nhs.uk/medicines-2/medicines-optimisation/ Accessed October 13 2020.
Shankar A, Shankar V, Praveen V. The Basics in research methodology: The clinical audit. J Clin Diag Res. 2011;5(3): 679-682.
Yorston D, Wormald R. Clinical auditing to improve patient outcomes. Community Eye Health. 2010;23(74):48-49.
Garriok J, Print A, Moody I. Medication Review of Patients with disability at Spectrum Care. Auckland: Spectrum Care; 2014. https://www.spectrumcare.org.nz/whanau/ Accessed October 13 2020.
Hughes CM, Cooper JA, Ryan C. Going beyond the numbers - a call to redefine polypharmacy. Br J Clin Pharmacol. 2014;77(6):915-916. https://doi.org/10.1111/bcp.12284
Hanlon J, Schmader K. What Types of Inappropriate prescribing predict adverse drug reactions in older adults? Ann Pharmacother. 2010;44(6):957-963. https://doi.org/10.1345/aph.1P182
Rueda J-R, Ballesteros J, Tejada M-I. Systematic review of pharmacological treatments in fragile X syndrome. BMC Neurology. 2009;9:53. https://doi.org/10.1186/1471-2377-9-53
Niven A, Goodey R, Webb A, Shankar R. The use of psychotropic medication for people with intellectual disabilities and behaviours that challenge in the context of a community multidisciplinary team approach. Br J Learn Disabil. 2018;46(1):4-9. https://doi.org/10.1111/bld.12206
Matson JL, Neal D. Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview. Res Dev Disabil. 2009;30(3):572-586. https://doi.org/10.1016/j.ridd.2008.08.007
Every-Palmer S, Newton-Howes G, Clarke MJ. Pharmacological treatment for antipsychotic-related constipation. Cochrane Database of Systematic Reviews. 2014;5:490-492. https://doi.org/10.1002/14651858.CD011128
Kamble P, Chen H, Sherer JT, Aparasu RR. Use of antipsychotics among elderly nursing home residents with dementia in the US. Drugs Aging. 2009;26(6):483-492. https://doi.org/10.2165/00002512-200926060-00005
Darowski A, Chambers S-A, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging. 2009;26:381-394. https://doi.org/10.2165/00002512-200926050-00002